EU green-lights Opdivo for melanoma; U.K. plans Bexsero vaccination drive;

> Bristol-Myers Squibb ($BMY) won European approval for its PD-1 immunotherapy Opdivo as a treatment for advanced melanoma, for first-line use as well as for patients who've been treated previously. Release

> The U.K. plans the world's first publicly funded vaccination drive against meningitis B, using Bexsero, the shot developed by Novartis ($NVS) and sold to GlaxoSmithKline ($GSK) in a multibillion-dollar asset swap earlier this year. Report

> A case series published in Diabetes Care advised that SGLT2 diabetes drugs only be used "with great caution" in patients with Type 1 diabetes. Report

> Pfizer's ($PFE) Centrum brand team rolled out a survey in Canada showing Canadians consume as many daily servings of caffeine as fruits and vegetables. Report

> A Texas judge decided that FDA labeling rules didn't pre-empt state regulations on off-label promotions in a case accusing a drugmaker of illegally marketing generic Cordarone for unapproved use. Report

And Finally...  Federal officials charged 11 people in a conspiracy to market millions of bottles of counterfeit 5-hour Energy drinks in the U.S. Report